DSIP vs Semax
Both DSIP and Semax are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
DSIP
Evidence CDelta Sleep-Inducing Peptide
A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
View full DSIP profile →Semax
Evidence BSemax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
View full Semax profile →Side-by-Side
| Attribute | DSIP | Semax |
|---|---|---|
| Evidence Grade | C | B |
| FDA Status | Not FDA-approved — research compound | Not FDA-approved in US — approved in Russia for stroke and cognitive disorders |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 200–600 mcg intranasal, morning |
| Clinics Indexed | 38 | 89 |
| Categories | sleep, neuroprotection | cognitive, neuroprotection |
Key reported benefits — DSIP
- ✓Slow-wave-sleep signals (preclinical)
- ✓Stress/cortisol modulation
- ✓Possible analgesic effect
Key reported benefits — Semax
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.